ethyl (6-chloro-2-(methylthio)-5-nitropyrimidin-4-yl)carbamate | 1434589-59-9

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: ethyl (6-chloro-2-(methylthio)-5-nitropyrimidin-4-yl)carbamate
• 英文别名: ethyl N-(6-chloro-2-methylsulfanyl-5-nitropyrimidin-4-yl)carbamate
• CAS: 1434589-59-9
• 化学式: C₈H₉ClN₄O₄S
• 分子量: 292.703
• InChiKey: BIWSPZXRCMEKCW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  135
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  ethyl (6-chloro-2-(methylthio)-5-nitropyrimidin-4-yl)carbamate 在 氨 作用下， 以 四氢呋喃 、 异丙醇 为溶剂， 反应 2.0h， 以100%的产率得到ethyl N-(6-amino-2-methylsulfanyl-5-nitropyrimidin-4-yl)carbamate
  参考文献：
  名称：

  [EN] MACROCYCLIC PURINES FOR THE TREATMENT OF VIRAL INFECTIONS
  [FR] PURINES MACROCYCLIQUES DESTINÉES AU TRAITEMENT D'INFECTIONS VIRALES

  摘要：

  这项发明涉及具有式(I)的大环嘌呤衍生物，其制备方法，药物组合物以及它们在治疗病毒感染中的应用。

  公开号：

  WO2014009509A1
• 作为产物：
  描述：

  2-甲硫基-4,6-二氯-5-硝基嘧啶 在 氨 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 9.0h， 生成 ethyl (6-chloro-2-(methylthio)-5-nitropyrimidin-4-yl)carbamate
  参考文献：
  名称：

  [EN] MACROCYCLIC TLR7 AGONIST, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF
  [FR] AGONISTE DE TLR7 MACROCYCLIQUE, SON PROCÉDÉ DE PRÉPARATION, COMPOSITION PHARMACEUTIQUE ET SON UTILISATION
  [ZH] 大环TLR7激动剂、其制备方法、药物组合物及其用途

  摘要：

  一种大环TLR7激动剂、其制备方法、药物组合物及其用途。公开的大环TLR7激动剂如式（I）所示，具有良好的TLR7激动活性，可用于治疗或预防肿瘤或由病毒引起的感染。

  公开号：

  WO2022063278A1

文献信息

• [EN] PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS<br/>[FR] DÉRIVÉS DE PURINE POUR LE TRAITEMENT D'INFECTIONS VIRALES
  申请人：JANSSEN R & D IRELAND

  公开号：WO2013068438A1

  公开（公告）日：2013-05-16

  The present invention relates to purine derivatives of formula (I), processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.

  本发明涉及式(I)的嘌呤衍生物，其制备方法，药物组合物以及它们在治疗病毒感染中的应用。
• [EN] MACROCYCLIC TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS<br/>[FR] AGONISTES MACROCYCLIQUES DU RÉCEPTEUR 7 DE TYPE TOLL (TLR7)
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2019209811A1

  公开（公告）日：2019-10-31

  Compounds having a structure according to formula are modulators of TLR7 activity and can be used to treat conditions amenable to treatment by the modulation of TLR7 activity.

  具有根据公式的结构的化合物是TLR7活性调节剂，可用于治疗可通过调节TLR7活性治疗的疾病。
• Purine derivatives for the treatment of viral infections
  申请人：JANSSEN SCIENCES IRELAND UC

  公开号：US10280167B2

  公开（公告）日：2019-05-07

  The present invention relates to purine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.

  本发明涉及嘌呤衍生物、其制备工艺、药物组合物及其在治疗病毒感染中的用途。
• Macrocyclic purines for the treatment of viral infections
  申请人：Janssen Sciences Ireland UC

  公开号：US10280180B2

  公开（公告）日：2019-05-07

  This invention relates macrocyclic purine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.

  本发明涉及大环嘌呤衍生物、其制备工艺、药物组合物及其在治疗病毒感染中的用途。
• Potent and Selective Inhibitors of MTH1 Probe Its Role in Cancer Cell Survival
  作者：Jason G. Kettle、Husam Alwan、Michal Bista、Jason Breed、Nichola L. Davies、Kay Eckersley、Shaun Fillery、Kevin M. Foote、Louise Goodwin、David R. Jones、Helena Käck、Alan Lau、J. Willem M. Nissink、Jon Read、James S. Scott、Ben Taylor、Graeme Walker、Lisa Wissler、Marta Wylot

  DOI：10.1021/acs.jmedchem.5b01760

  日期：2016.3.24

  Recent literature has claimed that inhibition of the enzyme MTH1 can eradicate cancer. MTH1 is one of the "housekeeping" enzymes that are responsible for hydrolyzing damaged nucleotides in cells and thus prevent them from being incorporated into DNA. We have developed orthogonal and chemically distinct tool compounds to those published in the literature to allow us to test the hypothesis that inhibition of MTH1 has wide applicability in the treatment of cancer. Here we present the work that led to the discovery of three structurally different series of MTH1 inhibitors with excellent potency, selectivity, and proven target engagement in cells. None of these compounds elicited the reported cellular phenotype, and additional siRNA and CRISPR experiments further support these observations. Critically, the difference between the responses of our highly selective inhibitors and published tool compounds suggests that the effect reported for the latter may be due to off-target cytotoxic effects. As a result, we conclude that the role of MTH1 in carcinogenesis and utility of its inhibition is yet to be established.